Harrow Partners with Three Healthcare Technology Platforms to Expand Access to Vevye

Harrow Partners with Three Healthcare Technology Platforms to Expand Access to Vevye

January 04, 2024

Harrow Pharmaceuticals announced strategic partnerships with three healthcare technology platforms, aiming to enhance the availability of its dry eye drug, Vevye (cyclosporine ophthalmic solution) 0.1%, in the United States. Vevye is a patented, non-preserved, twice-daily ophthalmic solution utilizing a water-free semifluorinated alkane (SFA) eye drop technology.

Vevye, dispensed in a 10-microliter drop, stands out as the first and only cyclosporine-based product indicated for treating both the signs and symptoms of dry eye disease (DED).

Market Access Partnerships for Vevye:

Harrow's collaboration with three key market access platforms aims to streamline the prescription life cycle, optimize patient access, and increase affordability for Vevye:

1. PhilRx:

● A patient access platform offering end-to-end visibility into the entire prescription life cycle.

● Simplifies the prior authorization process (PA) for physicians through one-click submission of PAs.

● Streamlines the insurance coverage process for patients.

● Enhances the likelihood of insurance reimbursement.

2. Apollo Care:

● A program specifically designed to establish and manage copay program deployment for Vevye.

● Focuses on optimizing patient access and affordability of the dry eye solution.

3. PARx Solutions:

● A web-based technology stack that aids prescribers in overcoming cumbersome challenges associated with prior authorizations.

● Provided free of charge to prescribers, PARx Solutions significantly reduces time-consuming obstacles related to prior authorizations.

"Harrow was founded on a commitment to patient access. Our 360-degree approach to market access for Vevye, including these new partnerships with PhilRx, Apollo Care, and PARx, is designed to ensure that all patients who can benefit from Vevye and who are prescribed Vevye, can get Vevye, said Mark L. Baum, Chairman and Chief Executive Officer of Harrow.

“We believe Vevye represents an important new prescription choice in the US dry eye disease market, and we are excited to streamline the prior authorization process, guiding patients through their insurance coverage and ensuring competitive pricing–with minimum hassle. Harrow’s Vevye market access program perfectly aligns with our commitment to providing physicians and their patients with innovative and affordable ophthalmic pharmaceutical products and the Harrow team eagerly anticipates the availability of Vevye – next week,” he added.